Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate

DRUG2 trials

Sponsors

Akeso, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Borderline Resectable Pancreatic CancerPancreatic Cancer

Phase 2

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

RecruitingNCT05859750

AkesoPancreatic Cancer

Start: 2023-05-25End: 2025-12-31Target: 78Updated: 2024-12-16

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical SciencesBorderline Resectable Pancreatic Cancer

Start: 2024-03-10End: 2025-12-24Target: 40Updated: 2024-04-03

Related Papers

Liposomal irinotecan combined with oxaliplatin, 5-fluorouracil/leucovorin with or without camrelizumab as preoperative chemotherapy for borderline resectable pancreatic cancer: Preliminary results of a single-center phase II exploratory study.

Journal of Clinical Oncology2026-05-28

Abstract CT145: A phase II, multicenter, open-label study (COMPASSION-26) of cadonilimab, a PD-1/CTLA-4 bispecific antibody,combined with chemotherapy (chemo) as first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC)

Cancer Research2026-04-17